Company: SXTPW
Filing Date: 2025-08-15
Form Type: PRE 14A
Source: 0001213900-25-077435
Chunk: 24

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-08-15
Form: PRE 14A
Chunk 24
---
 functions. The Code is available on our corporate website at
https://investors.60degreespharma.com/corporate-governance/governance-overview. The Code requires compliance with applicable law,
discusses how conflicts of interest are handled, requires familiarity with the Company’s disclosure requirements and provides for
waivers under certain circumstances. We intend to disclose any amendments to our code of business conduct and ethics, or waivers of its
requirements, on our website or in filings under the Exchange Act to the extent required by applicable rules and exchange requirements.

Board Leadership

The Nominating and Corporate Governance Committee
annually reviews the Board’s leadership structure and evaluates the performance and effectiveness of the Board. The Board retains
the authority to modify its leadership structure in order to stay current with our Company’s circumstances and advance the best
interests of the Company and its stockholders as and when appropriate. The Board’s annual self-evaluation includes questions regarding
the Board’s opportunities for open communication and the effectiveness of executive sessions.

Corporate Governance Policies and Practices

.

The Board undertakes an annual review of director
independence. During this review, the Board considers transactions and relationships between each director or any member of his or her
immediate family and the Company and its subsidiaries and affiliates. The purpose of this review is to determine whether any such relationships
or transactions were inconsistent with a determination that the director is independent. As a result of this review, the Board affirmatively
determined that three (3) of the five (5) of the directors are independent of the Company and its management under Nasdaq rules. Geoffrey
Dow and Cheryl Xu are not considered independent because of their employment by the Company.

<div align='center'>12</div>

In determining that the other directors did not
have a material relationship with the Company, the Board concluded that Messrs. Allen, Toovey and Field had no other relationship with
the Company other than their relationship as a director.

. The Audit Committee,
the Compensation Committee and the Nominating and Corporate Governance Committee of the Board operate pursuant to written charters. These
charters were approved by the Board and reflect certain best practices in corporate governance. These charters comply with the requirements
of the Nasdaq. Each charter is available on the Company’s website at: https://investors.60degreespharma.com/corporate-governance/governance-overview.

. Our non-management
directors meet in executive session at each regular Board meeting. The executive